Cancer Biomarker Market Analysis By Type (Breast, Prostate, Colorectal, Cervical, Liver, Lung Cancer), By Biomolecule (Genetic, Epigenetic, Metabolic, Proteomic), By Application, And Segment Forecasts, 2014 - 2025
出 版 商：Grand View Research Inc.
出版日期：2017/05/29
頁 數：85頁
文件格式：PDF
價 格：
USD 4,950 (Single-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
USD 7,950 (Multi-User License)
USD 9,950 (Global-User License)
The global cancer biomarkers market is expected to reach a value of USD 33.7 billion by 2025, based on a new report by Grand View Research, Inc. Growing initiatives for development of drugs targeting novel cancer biomarkers coupled with the introduction of technologically advanced companion diagnostic kits is estimated to provide the market with high growth potential. Increasing awareness about personalized medicines amongst patients is further anticipated to boost adoption of cancer biomarkers.
In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.
People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.
Further Key findings from the study suggest:
‧ Breast cancer was the largest segment by revenue share in 2016 owing to high prevalence of this type of cancer
‧ Lung cancer is estimated to be the fastest-growing type due to increasing research activities toward development of novel lung cancer biomarkers
‧ Genetic biomarkers, being the highest used and easily detectable held the majority share of cancer biomarker market by biomolecule in 2016
‧ However, epigenetic biomarkers are anticipated to witness lucrative growth due to increasing focus on finding the role of epigenetic modifications in cancer development
‧ Cancer biomarkers are majorly used for diagnostic purpose owing to their high specificity
‧ The personalized medicine segment is estimated to witness fastest CAGR of 15.0% over the forecast period
‧ North America dominated in terms of revenue share in 2016 due to established R&D infrastructure and high acceptance of biomarker-based cancer testing in this region
‧ Asia Pacific is anticipated to grow at a substantial growth rate till 2025 with CAGR of over 16.7%
‧ Some of the major companies in the cancer biomarkers market are Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company
In addition, presence of favorable government initiatives for the development of novel cancer diagnostic techniques is a key factor for market growth. For instance, the National Cancer Institute (NCI) provides funding to more than 8 research areas pertaining to cancer biomarker development. Cancer Research UK, Lung Cancer Research Foundation, and National Institutes of Health are some of the organizations providing funding for biomarker research.
People with high alcohol consumption, tobacco usage, unhealthy food habits, and sedentary lifestyle are reported to be 80% more at risk of developing cancer as compared to other individuals. Infections such as Human papillomavirus (HPV), Epstein-Barr virus, Hepatitis B virus, and Helicobacter pylori are also been studied to be related in cancer development.
Further Key findings from the study suggest:
‧ Breast cancer was the largest segment by revenue share in 2016 owing to high prevalence of this type of cancer
‧ Lung cancer is estimated to be the fastest-growing type due to increasing research activities toward development of novel lung cancer biomarkers
‧ Genetic biomarkers, being the highest used and easily detectable held the majority share of cancer biomarker market by biomolecule in 2016
‧ However, epigenetic biomarkers are anticipated to witness lucrative growth due to increasing focus on finding the role of epigenetic modifications in cancer development
‧ Cancer biomarkers are majorly used for diagnostic purpose owing to their high specificity
‧ The personalized medicine segment is estimated to witness fastest CAGR of 15.0% over the forecast period
‧ North America dominated in terms of revenue share in 2016 due to established R&D infrastructure and high acceptance of biomarker-based cancer testing in this region
‧ Asia Pacific is anticipated to grow at a substantial growth rate till 2025 with CAGR of over 16.7%
‧ Some of the major companies in the cancer biomarkers market are Abbott Laboratories; F.Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific Inc.; Affymetrix Inc.; Illumina, Inc.; Agilent Technologies; Merck & Co. Inc.; Hologic, Inc.; Sino Biological Inc.; and Becton, Dickinson and Company
Table of Contents
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.1.1. Purchased database:
1.1.2. GVR’s internal database
1.2. Research Methodology
1.3. Geographic Scope & Assumptions
1.4. Region-wise Market Calculation
1.4.1. Region-wise market: Base estimates
1.4.2. Global market: CAGR calculation
1.5. Region-based Segment Share Calculation
1.6. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Cancer Biomarkers Industry Outlook
3.1. Market Segmentation & Scope
3.1.1. Market driver analysis
3.1.1.1 Growing geriatric population base
3.1.1.2 Growing prevalence of cancer
3.1.1.3 Increasing government funding for cancer research
3.1.1.4 Technological advancements
3.1.2. Market restraint analysis
3.1.2.1 Large capital investments and production cost
3.2. Penetration & Growth Prospect Mapping
3.3. Cancer biomarkers - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4. Industry Analysis - Porter’s
Chapter 4. Cancer Biomarkers Market: Type Outlook
4.1. Cancer biomarkers market share by type, movement analysis
4.2. Breast cancer
4.2.1. Breast cancer Market estimates and forecast, 2014 - 2025 (USD Billion)
4.4. Prostate Cancer
4.4.1. Prostate cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.5. Colorectal Cancer
4.5.1. Colorectal cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.6. Cervical Cancer
4.6.1. Cervical cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.7. Liver Cancer
4.7.1. Liver cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.8. Lung Cancer
4.8.1. Lung cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.9. Others
4.9.1. Others market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 5. Cancer biomarkers Market: Biomolecule Estimates & Trend Analysis
5.1. Cancer Biomarkers Market: Biomolecule Movement Analysis
5.2. Genetic Biomarkers
5.2.1. Genetic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.3. Epigenetic Biomarkers
5.3.1. Epigenetic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.4. Metabolic Biomarkers
5.4.1. Metabolic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.5. Proteomic Biomarkers
5.5.1. Proteomic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.6. Others
5.6.1. Others market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 6. Cancer biomarkers Market: Application Estimates & Trend Analysis
6.1. Cancer Biomarkers Market: Application Movement Analysis
6.2. Drug Discovery
6.2.1. Drug discovery market estimates and forecast, 2014 - 2025 (USD Billion)
6.3. Diagnostics
6.3.1. Diagnostics market estimates and forecast, 2014 - 2025 (USD Billion)
6.4. Personalized Medicine
6.4.1. Personalized medicine market estimates and forecast, 2014 - 2025 (USD Billion)
6.5. Others
6.5.1. Others market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 7. Cancer Biomarkers Market: Regional Outlook
7.1. Cancer biomarkers market share by region, 2015 & 2025 (USD Billion)
7.2. North America
7.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.2.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.2.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.2.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.2.2. U.S.
7.2.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.2.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.2.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.2.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.2.3. Canada
7.2.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.2.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.2.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.2.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.3. Europe
7.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.3.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.3.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.3.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.3.2. Germany
7.3.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.3.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.3.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.3.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.3.3. UK
7.3.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.3.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.3.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.3.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4. Asia Pacific
7.4.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4.2. China
7.4.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4.3. India
7.4.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4.4. Japan
7.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.4.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.4.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.4.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.5. Latin America
7.5.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.5.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.5.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.5.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.5.2. Brazil
7.5.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.5.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.5.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.5.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.5.3. Mexico
7.5.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.5.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.5.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.5.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.6. Middle East & Africa
7.6.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.6.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.6.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.6.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.6.2. South Africa
7.6.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.6.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.6.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.6.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
Chapter 8. Company Profiles
8.1. Strategy Framework
8.2. Market Participation Categorization
8.3. Company Profiles
8.3.1. Abbott Laboratories
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. 9F. Hoffmann-La Roche Ltd
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Qiagen N.V
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Affymetrix Inc
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Illumina, Inc
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Agilent Technologies
8.3.6.1. Company overview
8.3.6.2. Financial overview
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Merck & Co. Inc
8.3.7.1. Company overview
8.3.7.2. Financial overview
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hologic, Inc.
8.3.8.1. Company overview
8.3.8.2. Financial overview
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Sino Biological Inc.
8.3.9.1. Company overview
8.3.9.2. Financial overview
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Thermo Fisher Scientific Inc.
8.3.10.1. Company overview
8.3.10.2. Financial overview
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Becton, Dickinson and Company
8.3.11.1. Company overview
8.3.11.2. Financial overview
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
Chapter 1. Methodology and Scope
1.1. Information Procurement
1.1.1. Purchased database:
1.1.2. GVR’s internal database
1.2. Research Methodology
1.3. Geographic Scope & Assumptions
1.4. Region-wise Market Calculation
1.4.1. Region-wise market: Base estimates
1.4.2. Global market: CAGR calculation
1.5. Region-based Segment Share Calculation
1.6. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Cancer Biomarkers Industry Outlook
3.1. Market Segmentation & Scope
3.1.1. Market driver analysis
3.1.1.1 Growing geriatric population base
3.1.1.2 Growing prevalence of cancer
3.1.1.3 Increasing government funding for cancer research
3.1.1.4 Technological advancements
3.1.2. Market restraint analysis
3.1.2.1 Large capital investments and production cost
3.2. Penetration & Growth Prospect Mapping
3.3. Cancer biomarkers - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4. Industry Analysis - Porter’s
Chapter 4. Cancer Biomarkers Market: Type Outlook
4.1. Cancer biomarkers market share by type, movement analysis
4.2. Breast cancer
4.2.1. Breast cancer Market estimates and forecast, 2014 - 2025 (USD Billion)
4.4. Prostate Cancer
4.4.1. Prostate cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.5. Colorectal Cancer
4.5.1. Colorectal cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.6. Cervical Cancer
4.6.1. Cervical cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.7. Liver Cancer
4.7.1. Liver cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.8. Lung Cancer
4.8.1. Lung cancer market estimates and forecast, 2014 - 2025 (USD Billion)
4.9. Others
4.9.1. Others market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 5. Cancer biomarkers Market: Biomolecule Estimates & Trend Analysis
5.1. Cancer Biomarkers Market: Biomolecule Movement Analysis
5.2. Genetic Biomarkers
5.2.1. Genetic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.3. Epigenetic Biomarkers
5.3.1. Epigenetic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.4. Metabolic Biomarkers
5.4.1. Metabolic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.5. Proteomic Biomarkers
5.5.1. Proteomic biomarkers market estimates and forecast, 2014 - 2025 (USD Billion)
5.6. Others
5.6.1. Others market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 6. Cancer biomarkers Market: Application Estimates & Trend Analysis
6.1. Cancer Biomarkers Market: Application Movement Analysis
6.2. Drug Discovery
6.2.1. Drug discovery market estimates and forecast, 2014 - 2025 (USD Billion)
6.3. Diagnostics
6.3.1. Diagnostics market estimates and forecast, 2014 - 2025 (USD Billion)
6.4. Personalized Medicine
6.4.1. Personalized medicine market estimates and forecast, 2014 - 2025 (USD Billion)
6.5. Others
6.5.1. Others market estimates and forecast, 2014 - 2025 (USD Billion)
Chapter 7. Cancer Biomarkers Market: Regional Outlook
7.1. Cancer biomarkers market share by region, 2015 & 2025 (USD Billion)
7.2. North America
7.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.2.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.2.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.2.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.2.2. U.S.
7.2.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.2.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.2.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.2.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.2.3. Canada
7.2.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.2.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.2.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.2.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.3. Europe
7.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.3.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.3.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.3.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.3.2. Germany
7.3.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.3.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.3.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.3.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.3.3. UK
7.3.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.3.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.3.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.3.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4. Asia Pacific
7.4.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4.2. China
7.4.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4.3. India
7.4.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.4.4. Japan
7.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.4.4.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.4.4.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.4.4.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.5. Latin America
7.5.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.5.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.5.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.5.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.5.2. Brazil
7.5.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.5.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.5.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.5.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.5.3. Mexico
7.5.3.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.5.3.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.5.3.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.5.3.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.6. Middle East & Africa
7.6.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.6.1.1. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.6.1.2. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.6.1.3. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
7.6.2. South Africa
7.6.2.1. Market estimates and forecast, 2014 - 2025 (USD Billion)
7.6.2.2. Market estimates and forecast by type, 2014 - 2025 (USD Billion)
7.6.2.3. Product market estimates and forecast by biomolecule, 2014 - 2025 (USD Billion)
7.6.2.4. Market estimates and forecast by application, 2014 - 2025 (USD Billion)
Chapter 8. Company Profiles
8.1. Strategy Framework
8.2. Market Participation Categorization
8.3. Company Profiles
8.3.1. Abbott Laboratories
8.3.1.1. Company overview
8.3.1.2. Financial performance
8.3.1.3. Product benchmarking
8.3.1.4. Strategic initiatives
8.3.2. 9F. Hoffmann-La Roche Ltd
8.3.2.1. Company overview
8.3.2.2. Financial performance
8.3.2.3. Product benchmarking
8.3.2.4. Strategic initiatives
8.3.3. Qiagen N.V
8.3.3.1. Company overview
8.3.3.2. Financial performance
8.3.3.3. Product benchmarking
8.3.3.4. Strategic initiatives
8.3.4. Affymetrix Inc
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. Illumina, Inc
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Agilent Technologies
8.3.6.1. Company overview
8.3.6.2. Financial overview
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Merck & Co. Inc
8.3.7.1. Company overview
8.3.7.2. Financial overview
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. Hologic, Inc.
8.3.8.1. Company overview
8.3.8.2. Financial overview
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Sino Biological Inc.
8.3.9.1. Company overview
8.3.9.2. Financial overview
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Thermo Fisher Scientific Inc.
8.3.10.1. Company overview
8.3.10.2. Financial overview
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Becton, Dickinson and Company
8.3.11.1. Company overview
8.3.11.2. Financial overview
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
